Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21366467 | 0.90 | NR4A3 (0.55) | NR4A3ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL13619749 | 0.87 | NR4A3 (0.52) | NR4A3ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL2854522 | 0.81 | MAPK1 (0.64) | MAPK1HPGDPOLB | |
| SCHEMBL10202150 | 0.80 | POLB (0.69) | ALDH1A1KDM4EHPGDPOLBMAPK14 | |
| SCHEMBL2854027 | 0.78 | ALDH1A1 (0.72) | ALDH1A1MAPTLMNAKDM4EHPGD | |
| SCHEMBL21357511 | 0.76 | ALDH1A1 (0.47) | NR4A3ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL21357581 | 0.75 | ALDH1A1 (0.68) | NR4A3ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL13101587 | 0.72 | RIPK1 (0.51) | ALDH1A1MAPTLMNAGAAKDM4E | |
| SCHEMBL12376656 | 0.70 | RIPK1 (0.58) | ALDH1A1MAPK1GAARIPK1 | |
| SCHEMBL2856945 | 0.69 | ALDH1A1 (0.81) | ALDH1A1MAPK1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| WO-2019175152-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | AXXAM S.P.A. (IT) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | NR4A3 91/4885ALDH1A1 1740/4885MAPK1 1194/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | NR4A3 91/4885ALDH1A1 1740/4885MAPK1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.